|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 31/4709 | (2006.01) |
| A61K 45/00 | (2013.01) | ||
| A61K 39/395 | (2006.01) | ||
| A61P 35/00 | (2018.01) | ||
| A61K 45/00 | (2006.01) | ||
| A61K 39/395 | (2013.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61K 31/4709 | (2013.01) | ||
| A61P 43/00 | (2006.01) | ||
| C07K 16/18 | (2013.01) | ||
| C07K 16/18 | (2006.01) | ||
| A61K 31/519 | (2013.01) |
| (11) | Patento numeris | 3421039 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 17756670.0 |
| Europos patento paraiškos padavimo data | 2017-02-24 | |
| (97) | Europos patento paraiškos paskelbimo data | 2019-01-02 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2021-10-06 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/JP2017/007219 |
| Data | 2017-02-24 |
| (87) | Numeris | WO 2017/146236 |
| Data | 2017-08-31 |
| (30) | Numeris | Data | Šalis |
| 2016035206 | 2016-02-26 | JP |
| (72) |
TANAKA, Kohei , JP
YASUHIRO, Tomoko , JP
|
| (73) |
ONO Pharmaceutical Co., Ltd. ,
1-5, Doshomachi 2-chome
Chuo-ku, Osaka-shi, Osaka 541-8526,
JP
|
| (54) | DRUG FOR CANCER THERAPY CHARACTERIZED BY ADMINISTERING COMBINATION BETWEEN AXL INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR |
| DRUG FOR CANCER THERAPY CHARACTERIZED BY ADMINISTERING COMBINATION BETWEEN AXL INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR |